Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

News SummaryMost relevantAll newsSector newsTweets 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
04/19/2012 | 07:50pm CEST

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
04/26 MERCK : America's Diabetes Challenge Unveils Common Challenges Affecting the Typ..
04/25 MERCK : America’s Diabetes Challenge Unveils Common Challenges Affecting t..
04/25 SAMSUNG BIOLOGICS : Bioepis to take on J&J with FDA approved Remicade biosimilar
04/25 PDL BIOPHARMA : rises in pre-market as Merck shells out US$19.5mln to settle pat..
04/24DJMERCK : Vaunted Ebola Vaccine Faces Questions
04/22 MERCK : Announces New Phase 2 Data on Investigational Triple Combination Therapy..
04/21 MERCK : Marc J Bern & Partners LLP Files Lawsuits For A Hundred Individuals Agai..
04/21 MERCK : Real-World Observational Study in the U.S. Veterans Affairs System Evalu..
04/20 MERCK : New Findings from Merck & Company in the Area of Animal Science Describe..
04/20 MERCK : Report Summarizes Mass Spectrometry Study Findings from Merck & Company ..
More news
Sector news : Pharmaceuticals - NEC
10:10aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
09:41aDJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
09:26aDJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
08:48aDJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
08:45aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/26 GLAXOSMITHKLINE : Good News, 2016's Positive Momentum Continues
04/26 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2017 Update
04/25 'SAFER' DOW DOGS : Put Visa In Top 3 For Gains, Per April Analyst Targets
04/25 TOP DOW DOGS : Chevron, Pfizer, & Merck For Gains, Per April Analyst Targets
04/25 WALL STREET BREAKFAST : Border Wall, Taxes And Tariffs
Financials ($)
Sales 2017 39 721 M
EBIT 2017 13 570 M
Net income 2017 7 454 M
Debt 2017 3 973 M
Yield 2017 2,99%
P/E ratio 2017 21,93
P/E ratio 2018 18,49
EV / Sales 2017 4,43x
EV / Sales 2018 4,28x
Capitalization 171 894 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,9 $
Spread / Average Target 9,9%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.6.51%171 894
JOHNSON & JOHNSON7.20%334 822
ROCHE HOLDING LTD.10.83%223 653
PFIZER INC.3.94%201 581
NOVARTIS AG2.77%201 384
SANOFI11.38%120 619
More Results